{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:11:42Z","timestamp":1794521502808,"version":"4.9.1"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41574-025-01197-7","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:45:26Z","timestamp":1762335926000},"page":"139-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Sarcopenia and MASLD: novel insights and the future"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-3039","authenticated-orcid":false,"given":"Chang-Hai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-222X","authenticated-orcid":false,"given":"Qing-Min","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-1007","authenticated-orcid":false,"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-8050","authenticated-orcid":false,"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-8158","authenticated-orcid":false,"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0267","authenticated-orcid":false,"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-6693","authenticated-orcid":false,"given":"Isabelle Anne","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8947","authenticated-orcid":false,"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9790-6225","authenticated-orcid":false,"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"1197_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1197_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1197_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng, G. et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 21, 46\u201356 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1197_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/jcsm.12651","volume":"12","author":"A Kitamura","year":"2021","unstructured":"Kitamura, A. et al. Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J. Cachexia Sarcopenia Muscle 12, 30\u201338 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR5","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.jhepr.2024.101113","volume":"6","author":"E Dajti","year":"2024","unstructured":"Dajti, E. et al. Sarcopenia evaluated by EASL\/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: a systematic review and meta-analysis. JHEP Rep. 6, 101113 (2024).","journal-title":"JHEP Rep."},{"key":"1197_CR6","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1016\/j.cgh.2023.02.013","volume":"21","author":"M Harring","year":"2023","unstructured":"Harring, M. et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin. Gastroenterol. Hepatol. 21, 2876\u20132888.e5 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1197_CR7","first-page":"485","volume":"1","author":"T Addison","year":"1836","unstructured":"Addison, T. Observations on fatty degeneration of the liver. Guys Hosp. Rep. 1, 485 (1836).","journal-title":"Guys Hosp. Rep."},{"key":"1197_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam, M., Sanyal, A. J. & George, J.; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999\u20132014.e1 (2020).","journal-title":"Gastroenterology"},{"key":"1197_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"1197_CR10","doi-asserted-by":"publisher","first-page":"155664","DOI":"10.1016\/j.metabol.2023.155664","volume":"147","author":"M Kokkorakis","year":"2023","unstructured":"Kokkorakis, M., Boutari, C., Katsiki, N. & Mantzoros, C. S. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism 147, 155664 (2023).","journal-title":"Metabolism"},{"key":"1197_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17446651.2025.2492767","volume":"20","author":"M Jiang","year":"2025","unstructured":"Jiang, M. et al. MAFLD vs. MASLD: a year in review. Expert Rev. Endocrinol. Metab. 20, 267\u2013278 (2025).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1197_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100019","volume":"1","author":"M Eslam","year":"2023","unstructured":"Eslam, M. & George, J. Two years on, a perspective on MAFLD. eGastroenterology 1, e100019 (2023).","journal-title":"eGastroenterology"},{"key":"1197_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","volume":"13","author":"F Abdelhameed","year":"2024","unstructured":"Abdelhameed, F. et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD. Curr. Obes. Rep. 13, 510\u2013531 (2024).","journal-title":"Curr. Obes. Rep."},{"key":"1197_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO).","year":"2024","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"1197_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki, N., Ajmera, V. & Loomba, R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat. Rev. Endocrinol. 18, 55\u201366 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1197_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","volume":"37","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab. 37, 59\u201368.e3 (2025).","journal-title":"Cell Metab."},{"key":"1197_CR17","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","volume":"74","author":"G Feng","year":"2025","unstructured":"Feng, G., Wong, V. W., Targher, G., Byrne, C. D. & Zheng, M. H. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut 74, 1741\u20131750 (2025).","journal-title":"Gut"},{"key":"1197_CR18","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393, 2636\u20132646 (2019).","journal-title":"Lancet"},{"key":"1197_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12603-019-1267-x","volume":"24","author":"SK Papadopoulou","year":"2020","unstructured":"Papadopoulou, S. K., Tsintavis, P., Potsaki, P. & Papandreou, D. Differences in the prevalence of sarcopenia in community-dwelling, nursing home and hospitalized individuals. a systematic review and meta-analysis. J. Nutr. Health Aging 24, 83\u201390 (2020).","journal-title":"J. Nutr. Health Aging"},{"key":"1197_CR20","doi-asserted-by":"publisher","first-page":"155585","DOI":"10.1016\/j.metabol.2023.155585","volume":"144","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto, Y., Takahashi, F., Okamura, T., Hamaguchi, M. & Fukui, M. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes. Metabolism 144, 155585 (2023).","journal-title":"Metabolism"},{"key":"1197_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft, A. J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48, 16\u201331 (2019).","journal-title":"Age Ageing"},{"key":"1197_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen, L. K. et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 21, 300\u2013307.e2 (2020).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1197_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/jcm8030322","volume":"8","author":"MH Jo","year":"2019","unstructured":"Jo, M. H. et al. Predictors of discordance in the assessment of skeletal muscle mass between computed tomography and bioimpedance analysis. J. Clin. Med. 8, 322 (2019).","journal-title":"J. Clin. Med."},{"key":"1197_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14218\/JCTH.2020.00065","volume":"8","author":"S Altajar","year":"2020","unstructured":"Altajar, S. & Baffy, G. Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease. J. Clin. Transl. Hepatol. 8, 414\u2013423 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1197_CR25","doi-asserted-by":"publisher","first-page":"155717","DOI":"10.1016\/j.metabol.2023.155717","volume":"150","author":"SA Polyzos","year":"2024","unstructured":"Polyzos, S. A. & Mantzoros, C. S. Sarcopenia: still in relative definition-penia and severe treatment-penia. Metabolism 150, 155717 (2024).","journal-title":"Metabolism"},{"key":"1197_CR26","doi-asserted-by":"publisher","first-page":"155558","DOI":"10.1016\/j.metabol.2023.155558","volume":"143","author":"R Barazzoni","year":"2023","unstructured":"Barazzoni, R., Cederholm, T., Zanetti, M. & Gortan Cappellari, G. Defining and diagnosing sarcopenia: is the glass now half full? Metabolism 143, 155558 (2023).","journal-title":"Metabolism"},{"key":"1197_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12783","volume":"13","author":"F Petermann-Rocha","year":"2022","unstructured":"Petermann-Rocha, F. et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 13, 86\u201399 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR28","doi-asserted-by":"publisher","first-page":"155533","DOI":"10.1016\/j.metabol.2023.155533","volume":"144","author":"S Yuan","year":"2023","unstructured":"Yuan, S. & Larsson, S. C. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism 144, 155533 (2023).","journal-title":"Metabolism"},{"key":"1197_CR29","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/jcsm.13543","volume":"15","author":"MJ Kim","year":"2024","unstructured":"Kim, M. J. et al. Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography. J. Cachexia Sarcopenia Muscle 15, 1942\u20131952 (2024).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","volume":"21","author":"YC Hsieh","year":"2023","unstructured":"Hsieh, Y. C. et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin. Gastroenterol. Hepatol. 21, 388\u2013397.e10 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1197_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","volume":"14","author":"JA Batsis","year":"2018","unstructured":"Batsis, J. A. & Villareal, D. T. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat. Rev. Endocrinol. 14, 513\u2013537 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1197_CR32","doi-asserted-by":"publisher","first-page":"155639","DOI":"10.1016\/j.metabol.2023.155639","volume":"146","author":"CL Axelrod","year":"2023","unstructured":"Axelrod, C. L., Dantas, W. S. & Kirwan, J. P. Sarcopenic obesity: emerging mechanisms and therapeutic potential. Metabolism 146, 155639 (2023).","journal-title":"Metabolism"},{"key":"1197_CR33","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s40520-019-01277-5","volume":"31","author":"V Atmis","year":"2019","unstructured":"Atmis, V. et al. The relationship between all-cause mortality sarcopenia and sarcopenic obesity among hospitalized older people. Aging Clin. Exp. Res. 31, 1563\u20131572 (2019).","journal-title":"Aging Clin. Exp. Res."},{"key":"1197_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102164","volume":"93","author":"S Eitmann","year":"2024","unstructured":"Eitmann, S. et al. Obesity paradox in older sarcopenic adults \u2014 a delay in aging: a systematic review and meta-analysis. Ageing Res. Rev. 93, 102164 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1197_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.70013","volume":"16","author":"L Yang","year":"2025","unstructured":"Yang, L. et al. The combination of fat distribution and BMI redefines obesity: result from NHANES. J. Cachexia Sarcopenia Muscle 16, e70013 (2025).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR36","first-page":"501","volume":"74","author":"W Li","year":"2024","unstructured":"Li, W. & Wang, W. Unravelling the obesity paradox in MASLD patients with extrahepatic cancer. Gut 74, 501\u2013503 (2024).","journal-title":"Gut"},{"key":"1197_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jacc.2012.10.035","volume":"61","author":"T Coutinho","year":"2013","unstructured":"Coutinho, T. et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of \u201cnormal weight central obesity\u201d. J. Am. Coll. Cardiol. 61, 553\u2013560 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1197_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82751-7","volume":"14","author":"X Wu","year":"2024","unstructured":"Wu, X., Chen, Z., Zhao, Y. & Ren, H. Correlation and predictive value of novel anthropometric indicators with adult sarcopenia and sarcopenia obesity. Sci. Rep. 14, 31776 (2024).","journal-title":"Sci. Rep."},{"key":"1197_CR39","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s41999-024-01024-8","volume":"15","author":"M Guner","year":"2024","unstructured":"Guner, M. et al. Evaluation of waist-to-calf ratio as a diagnostic tool for sarcopenic obesity: a cross-sectional study from a geriatric outpatient clinic. Eur. Geriatr. Med. 15, 1469\u20131475 (2024).","journal-title":"Eur. Geriatr. Med."},{"key":"1197_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078933","volume":"14","author":"C Deng","year":"2024","unstructured":"Deng, C., Ou, Q., Ou, X. & Pan, D. Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis. BMJ Open 14, e078933 (2024).","journal-title":"BMJ Open"},{"key":"1197_CR41","doi-asserted-by":"publisher","first-page":"155676","DOI":"10.1016\/j.metabol.2023.155676","volume":"147","author":"SA Polyzos","year":"2023","unstructured":"Polyzos, S. A., Vachliotis, I. D. & Mantzoros, C. S. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. Metabolism 147, 155676 (2023).","journal-title":"Metabolism"},{"key":"1197_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clnu.2017.11.021","volume":"38","author":"TC Peng","year":"2019","unstructured":"Peng, T. C. et al. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): the importance of sarcopenia definition. Clin. Nutr. 38, 422\u2013428 (2019).","journal-title":"Clin. Nutr."},{"key":"1197_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/sci6040059","volume":"6","author":"J Rigor","year":"2024","unstructured":"Rigor, J., Soares, M. M., Barata, P. & Mendes, D. M. How sarcopenia, muscle mass, strength, and performance relate to non-alcoholic fatty liver disease: a systematic review. Sci. 6, 59 (2024).","journal-title":"Sci."},{"key":"1197_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.02.051","volume":"63","author":"YH Lee","year":"2015","unstructured":"Lee, Y. H. et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J. Hepatol. 63, 486\u2013493 (2015).","journal-title":"J. Hepatol."},{"key":"1197_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo, B. K. et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J. Hepatol. 66, 123\u2013131 (2017).","journal-title":"J. Hepatol."},{"key":"1197_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5009\/gnl230238","volume":"18","author":"E Han","year":"2023","unstructured":"Han, E. et al. Appendicular skeletal muscle mass to visceral fat area ratio predicts hepatic morbidities. Gut Liver 18, 509\u2013519 (2023).","journal-title":"Gut Liver"},{"key":"1197_CR47","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.cgh.2022.11.031","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun, H. S. et al. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 21, 2298\u20132307.e18 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1197_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3350\/cmh.2023.0035","volume":"29","author":"HK Kim","year":"2023","unstructured":"Kim, H. K. et al. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity. Clin. Mol. Hepatol. 29, 987\u20131001 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"1197_CR49","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/j.jhep.2023.09.030","volume":"80","author":"T Yang","year":"2024","unstructured":"Yang, T., Yin, J., Li, J. & Wang, Q. The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention. J. Hepatol. 80, e82\u2013e85 (2024).","journal-title":"J. Hepatol."},{"key":"1197_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jhep.2022.01.010","volume":"76","author":"F Petermann-Rocha","year":"2022","unstructured":"Petermann-Rocha, F. et al. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK biobank participants. J. Hepatol. 76, 1021\u20131029 (2022).","journal-title":"J. Hepatol."},{"key":"1197_CR51","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep4.1975","volume":"6","author":"Y Cho","year":"2022","unstructured":"Cho, Y. et al. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol. Commun. 6, 2238\u20132252 (2022).","journal-title":"Hepatol. Commun."},{"key":"1197_CR52","doi-asserted-by":"publisher","first-page":"584","DOI":"10.14309\/ajg.0000000000000572","volume":"115","author":"E Han","year":"2020","unstructured":"Han, E. et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am. J. Gastroenterol. 115, 584\u2013595 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1197_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41387-023-00250-6","volume":"13","author":"Q Zhao","year":"2023","unstructured":"Zhao, Q., Yin, Y. & Deng, Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr. Diabetes 13, 21 (2023).","journal-title":"Nutr. Diabetes"},{"key":"1197_CR54","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/jcsm.12719","volume":"12","author":"JH Moon","year":"2021","unstructured":"Moon, J. H., Koo, B. K. & Kim, W. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. J. Cachexia Sarcopenia Muscle 12, 964\u2013972 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100171","volume":"2","author":"P Golabi","year":"2020","unstructured":"Golabi, P. et al. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep. 2, 100171 (2020).","journal-title":"JHEP Rep."},{"key":"1197_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17115","volume":"7","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Sarcopenic obesity and outcomes for patients with cancer. JAMA Netw. Open 7, e2417115 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1197_CR57","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.clnu.2022.03.022","volume":"41","author":"M Kouvari","year":"2022","unstructured":"Kouvari, M. et al. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: data from the ATTICA cohort study. Clin. Nutr. 41, 1281\u20131289 (2022).","journal-title":"Clin. Nutr."},{"key":"1197_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3604","volume":"7","author":"E Benz","year":"2024","unstructured":"Benz, E. et al. Sarcopenia and sarcopenic obesity and mortality among older people. JAMA Netw. Open 7, e243604 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1197_CR59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4093\/dmj.2021.0355","volume":"47","author":"Y Cho","year":"2023","unstructured":"Cho, Y. et al. Non-alcoholic fatty liver disease with sarcopenia and carotid plaque progression risk in patients with type 2 diabetes mellitus. Diabetes Metab. J. 47, 232\u2013241 (2023).","journal-title":"Diabetes Metab. J."},{"key":"1197_CR60","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/hep.30049","volume":"68","author":"G Kim","year":"2018","unstructured":"Kim, G. et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology 68, 1755\u20131768 (2018).","journal-title":"Hepatology"},{"key":"1197_CR61","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/obr.12776","volume":"20","author":"CH De Fre","year":"2019","unstructured":"De Fre, C. H. et al. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity? Obes. Rev. 20, 353\u2013363 (2019).","journal-title":"Obes. Rev."},{"key":"1197_CR62","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/jcsm.12901","volume":"13","author":"CW Li","year":"2022","unstructured":"Li, C. W. et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J. Cachexia Sarcopenia Muscle 13, 781\u2013794 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR63","doi-asserted-by":"publisher","first-page":"155577","DOI":"10.1016\/j.metabol.2023.155577","volume":"144","author":"MJ Park","year":"2023","unstructured":"Park, M. J. & Choi, K. M. Interplay of skeletal muscle and adipose tissue: sarcopenic obesity. Metabolism 144, 155577 (2023).","journal-title":"Metabolism"},{"key":"1197_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 92, 82\u201397 (2019).","journal-title":"Metabolism"},{"key":"1197_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105807","volume":"172","author":"L Yin","year":"2021","unstructured":"Yin, L. et al. Skeletal muscle atrophy: from mechanisms to treatments. Pharmacol. Res. 172, 105807 (2021).","journal-title":"Pharmacol. Res."},{"key":"1197_CR66","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1073\/pnas.0705408104","volume":"104","author":"KF Petersen","year":"2007","unstructured":"Petersen, K. F. et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104, 12587\u201312594 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1197_CR67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo, A., Nascimbeni, F., Mantovani, A. & Targher, G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J. Hepatol. 68, 335\u2013352 (2018).","journal-title":"J. Hepatol."},{"key":"1197_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2337\/db12-0905","volume":"62","author":"SB Bender","year":"2013","unstructured":"Bender, S. B., McGraw, A. P., Jaffe, I. Z. & Sowers, J. R. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 62, 313\u2013319 (2013).","journal-title":"Diabetes"},{"key":"1197_CR69","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/jcsm.13518","volume":"15","author":"KZ Zhang","year":"2024","unstructured":"Zhang, K. Z. et al. RBP4 promotes denervation-induced muscle atrophy through STRA6-dependent pathway. J. Cachexia Sarcopenia Muscle 15, 1601\u20131615 (2024).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR70","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","volume":"75","author":"YC Zhao","year":"2020","unstructured":"Zhao, Y. C. et al. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension 75, 275\u2013284 (2020).","journal-title":"Hypertension"},{"key":"1197_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31\u201355 (2022).","journal-title":"Immunity"},{"key":"1197_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000518407","volume":"14","author":"M Nati","year":"2022","unstructured":"Nati, M., Chung, K. J. & Chavakis, T. The role of innate immune cells in nonalcoholic fatty liver disease. J. Innate Immun. 14, 31\u201341 (2022).","journal-title":"J. Innate Immun."},{"key":"1197_CR73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","volume":"36","author":"J Mauer","year":"2015","unstructured":"Mauer, J., Denson, J. L. & Bruning, J. C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 36, 92\u2013101 (2015).","journal-title":"Trends Immunol."},{"key":"1197_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbalip.2018.12.003","volume":"1864","author":"C Fang","year":"2019","unstructured":"Fang, C. et al. Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864, 271\u2013280 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"1197_CR75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12979-022-00320-w","volume":"19","author":"A Rakib","year":"2022","unstructured":"Rakib, A., Kiran, S., Mandal, M. & Singh, U. P. MicroRNAs: a crossroad that connects obesity to immunity and aging. Immun. Ageing 19, 64 (2022).","journal-title":"Immun. Ageing"},{"key":"1197_CR76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 17, 279\u2013297 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1197_CR77","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmet.2015.10.001","volume":"22","author":"P Kovatcheva-Datchary","year":"2015","unstructured":"Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab. 22, 971\u2013982 (2015).","journal-title":"Cell Metab."},{"key":"1197_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s12223-025-01283-3","author":"T Fukuoka","year":"2025","unstructured":"Fukuoka, T. et al. Alteration of the intestinal microbiota associated with the development of nonalcoholic steatohepatitis and sarcopenia in SHRSP5\/Dmcr. Folia Microbiol. https:\/\/doi.org\/10.1007\/s12223-025-01283-3 (2025).","journal-title":"Folia Microbiol."},{"key":"1197_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clnu.2025.04.004","volume":"49","author":"L Wang","year":"2025","unstructured":"Wang, L., He, X., Zhang, Z. & Chen, N. Distinct gut microbiota signatures in older people with sarcopenic obesity and sarcopenia without obesity. Clin. Nutr. 49, 77\u201389 (2025).","journal-title":"Clin. Nutr."},{"key":"1197_CR80","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/jcsm.12964","volume":"13","author":"M Giron","year":"2022","unstructured":"Giron, M., Thomas, M., Dardevet, D., Chassard, C. & Savary-Auzeloux, I. Gut microbes and muscle function: can probiotics make our muscles stronger? J. Cachexia Sarcopenia Muscle 13, 1460\u20131476 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR81","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/jcsm.12784","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Understanding the gut microbiota and sarcopenia: a systematic review. J. Cachexia Sarcopenia Muscle 12, 1393\u20131407 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","volume":"20","author":"H Tilg","year":"2020","unstructured":"Tilg, H., Zmora, N., Adolph, T. E. & Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 20, 40\u201354 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1197_CR83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora, E. E., Meex, R. C. R., Venema, K. & Blaak, E. E. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat. Rev. Endocrinol. 15, 261\u2013273 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1197_CR84","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s42255-020-0188-7","volume":"2","author":"J Frampton","year":"2020","unstructured":"Frampton, J., Murphy, K. G., Frost, G. & Chambers, E. S. Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. Nat. Metab. 2, 840\u2013848 (2020).","journal-title":"Nat. Metab."},{"key":"1197_CR85","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805\u2013820 (2010).","journal-title":"Cell"},{"key":"1197_CR86","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","volume":"67","author":"W Jia","year":"2023","unstructured":"Jia, W., Li, Y., Cheung, K. C. P. & Zheng, X. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. Sci. China Life Sci. 67, 865\u2013878 (2023).","journal-title":"Sci. China Life Sci."},{"key":"1197_CR87","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1002\/jcsm.13062","volume":"13","author":"M Eggelbusch","year":"2022","unstructured":"Eggelbusch, M. et al. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle. J. Cachexia Sarcopenia Muscle 13, 3048\u20133061 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2025.101138","volume":"11","author":"J Lu","year":"2025","unstructured":"Lu, J. et al. Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Curr. Res. Food Sci. 11, 101138 (2025).","journal-title":"Curr. Res. Food Sci."},{"key":"1197_CR89","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13167-025-00398-4","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang, S. et al. Association of prebiotic\/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework. EPMA J. 16, 183\u2013197 (2025).","journal-title":"EPMA J."},{"key":"1197_CR90","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","volume":"31","author":"H Saeed","year":"2025","unstructured":"Saeed, H. et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S94\u2013S111 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1197_CR91","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","volume":"158","author":"E Scorletti","year":"2020","unstructured":"Scorletti, E. et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology 158, 1597\u20131610.e7 (2020).","journal-title":"Gastroenterology"},{"key":"1197_CR92","doi-asserted-by":"publisher","first-page":"e1693","DOI":"10.1093\/nutrit\/nuae145","volume":"83","author":"M Besora-Moreno","year":"2025","unstructured":"Besora-Moreno, M., Llaurado, E., Valls, R. M., Pedret, A. & Sola, R. Effects of probiotics, prebiotics, and synbiotics on sarcopenia parameters in older adults: a systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 83, e1693\u2013e1708 (2025).","journal-title":"Nutr. Rev."},{"key":"1197_CR93","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/nu17142332","volume":"17","author":"JE Moreira-Velasco","year":"2025","unstructured":"Moreira-Velasco, J. E., Contreras-Alvarado, M. F., Rammal, H., Rivas, D. & Duque, G. Beyond calcium and vitamin D: exploring creatine, beta-hydroxy-beta-methylbutyrate, prebiotics and probiotics in osteosarcopenia. Nutrients 17, 2332 (2025).","journal-title":"Nutrients"},{"key":"1197_CR94","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","volume":"12","author":"L Xue","year":"2022","unstructured":"Xue, L., Deng, Z., Luo, W., He, X. & Chen, Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front. Cell Infect. Microbiol. 12, 759306 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1197_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06557-5","volume":"23","author":"B Yang","year":"2025","unstructured":"Yang, B. et al. The efficacy and safety of fecal microbiota transplantation in the treatment of sarcopenia: a retrospective study. J. Transl. Med. 23, 645 (2025).","journal-title":"J. Transl. Med."},{"key":"1197_CR96","doi-asserted-by":"publisher","first-page":"155711","DOI":"10.1016\/j.metabol.2023.155711","volume":"149","author":"MA Aslam","year":"2023","unstructured":"Aslam, M. A., Ma, E. B. & Huh, J. Y. Pathophysiology of sarcopenia: genetic factors and their interplay with environmental factors. Metabolism 149, 155711 (2023).","journal-title":"Metabolism"},{"key":"1197_CR97","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/apt.15372","volume":"50","author":"MF Xia","year":"2019","unstructured":"Xia, M. F. et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng study. Aliment. Pharmacol. Ther. 50, 684\u2013695 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1197_CR98","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","volume":"81","author":"A Ahmed","year":"2024","unstructured":"Ahmed, A., Cule, M., Bell, J. D., Sattar, N. & Yaghootkar, H. Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J. Hepatol. 81, 921\u2013929 (2024).","journal-title":"J. Hepatol."},{"key":"1197_CR99","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi, O. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3614\u20133623 (2024).","journal-title":"Nat. Med."},{"key":"1197_CR100","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Trepo","year":"2020","unstructured":"Trepo, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196\u20131209 (2020).","journal-title":"J. Hepatol."},{"key":"1197_CR101","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","volume":"164","author":"VL Chen","year":"2023","unstructured":"Chen, V. L. et al. PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 164, 966\u2013977.e17 (2023).","journal-title":"Gastroenterology"},{"key":"1197_CR102","doi-asserted-by":"publisher","first-page":"156057","DOI":"10.1016\/j.metabol.2024.156057","volume":"161","author":"K Stefanakis","year":"2024","unstructured":"Stefanakis, K., Kokkorakis, M. & Mantzoros, C. S. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 161, 156057 (2024).","journal-title":"Metabolism"},{"key":"1197_CR103","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.3390\/nu7115459","volume":"7","author":"C Davis","year":"2015","unstructured":"Davis, C., Bryan, J., Hodgson, J. & Murphy, K. Definition of the Mediterranean diet; a literature review. Nutrients 7, 9139\u20139153 (2015).","journal-title":"Nutrients"},{"key":"1197_CR104","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Lifestyle interventions in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 708\u2013722 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1197_CR105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13679-022-00481-1","volume":"11","author":"G Muscogiuri","year":"2022","unstructured":"Muscogiuri, G. et al. Mediterranean diet and obesity-related disorders: what is the evidence? Curr. Obes. Rep. 11, 287\u2013304 (2022).","journal-title":"Curr. Obes. Rep."},{"key":"1197_CR106","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/nbu.12707","volume":"49","author":"A Sualeheen","year":"2024","unstructured":"Sualeheen, A. et al. Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, western countries: what\u2019s known and what\u2019s needed? Nutr. Bull. 49, 444\u2013462 (2024).","journal-title":"Nutr. Bull."},{"key":"1197_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155637","volume":"146","author":"R Calvani","year":"2023","unstructured":"Calvani, R. et al. Diet for the prevention and management of sarcopenia. Metabolism 146, 155637 (2023).","journal-title":"Metabolism"},{"key":"1197_CR108","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/molecules26040985","volume":"26","author":"A Nani","year":"2021","unstructured":"Nani, A., Murtaza, B., Sayed Khan, A., Khan, N. A. & Hichami, A. Antioxidant and anti-inflammatory potential of polyphenols contained in mediterranean diet in obesity: molecular mechanisms. Molecules 26, 985 (2021).","journal-title":"Molecules"},{"key":"1197_CR109","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.37994","volume":"6","author":"J Konieczna","year":"2023","unstructured":"Konieczna, J. et al. An energy-reduced Mediterranean diet, physical activity, and body composition: an interim subgroup analysis of the PREDIMED-plus randomized clinical trial. JAMA Netw. Open 6, e2337994 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1197_CR110","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","volume":"399","author":"J Delgado-Lista","year":"2022","unstructured":"Delgado-Lista, J. et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399, 1876\u20131885 (2022).","journal-title":"Lancet"},{"key":"1197_CR111","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","volume":"70","author":"A Yaskolka Meir","year":"2021","unstructured":"Yaskolka Meir, A. et al. Effect of green-mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 70, 2085\u20132095 (2021).","journal-title":"Gut"},{"key":"1197_CR112","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jacc.2020.07.049","volume":"76","author":"JH O\u2019Keefe","year":"2020","unstructured":"O\u2019Keefe, J. H. et al. A pesco-Mediterranean diet with intermittent fasting: JACC review topic of the week. J. Am. Coll. Cardiol. 76, 1484\u20131493 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1197_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1017\/S0029665123003555","volume":"82","author":"CH Murphy","year":"2023","unstructured":"Murphy, C. H., McCarthy, S. N. & Roche, H. M. Nutrition strategies to counteract sarcopenia: a focus on protein, LC n-3 PUFA and precision nutrition. Proc. Nutr. Soc. 82, 419\u2013431 (2023).","journal-title":"Proc. Nutr. Soc."},{"key":"1197_CR114","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.clnu.2014.04.007","volume":"33","author":"NE Deutz","year":"2014","unstructured":"Deutz, N. E. et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin. Nutr. 33, 929\u2013936 (2014).","journal-title":"Clin. Nutr."},{"key":"1197_CR115","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/liv.14596","volume":"40","author":"C Xu","year":"2020","unstructured":"Xu, C. et al. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. Liver Int. 40, 2982\u20132997 (2020).","journal-title":"Liver Int."},{"key":"1197_CR116","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.nut.2013.11.008","volume":"30","author":"AH Kani","year":"2014","unstructured":"Kani, A. H., Alavian, S. M., Esmaillzadeh, A., Adibi, P. & Azadbakht, L. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: a parallel randomized trial. Nutrition 30, 814\u2013821 (2014).","journal-title":"Nutrition"},{"key":"1197_CR117","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cmet.2024.10.001","volume":"36","author":"Y Liao","year":"2024","unstructured":"Liao, Y. et al. Amino acid is a major carbon source for hepatic lipogenesis. Cell Metab. 36, 2437\u20132448.e8 (2024).","journal-title":"Cell Metab."},{"key":"1197_CR118","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1681\/ASN.2020010028","volume":"31","author":"GJ Ko","year":"2020","unstructured":"Ko, G. J., Rhee, C. M., Kalantar-Zadeh, K. & Joshi, S. The effects of high-protein diets on kidney health and longevity. J. Am. Soc. Nephrol. 31, 1667\u20131679 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1197_CR119","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/nu11020316","volume":"11","author":"L Oliva","year":"2019","unstructured":"Oliva, L., Alemany, M., Remesar, X. & Fernandez-Lopez, J. A. The food energy\/protein ratio regulates the rat urea cycle but not total nitrogen losses. Nutrients 11, 316 (2019).","journal-title":"Nutrients"},{"key":"1197_CR120","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ueg2.12443","volume":"11","author":"A Hadefi","year":"2023","unstructured":"Hadefi, A., Arvanitakis, M., Trepo, E. & Zelber-Sagi, S. Dietary strategies in non-alcoholic fatty liver disease patients: from evidence to daily clinical practice, a systematic review. U. Eur. Gastroenterol. J. 11, 663\u2013689 (2023).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1197_CR121","doi-asserted-by":"publisher","first-page":"24441","DOI":"10.18632\/aging.103987","volume":"12","author":"WQ Xie","year":"2020","unstructured":"Xie, W. Q. et al. Caloric restriction: implications for sarcopenia and potential mechanisms. Aging 12, 24441\u201324452 (2020).","journal-title":"Aging"},{"key":"1197_CR122","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/nu13030814","volume":"13","author":"J Buren","year":"2021","unstructured":"Buren, J., Ericsson, M., Damasceno, N. R. T. & Sjodin, A. A ketogenic low-carbohydrate high-fat diet increases LDL cholesterol in healthy, young, normal-weight women: a randomized controlled feeding trial. Nutrients 13, 814 (2021).","journal-title":"Nutrients"},{"key":"1197_CR123","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/joim.13639","volume":"294","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Low-carbohydrate diets, low-fat diets, and mortality in middle-aged and older people: a prospective cohort study. J. Intern. Med. 294, 203\u2013215 (2023).","journal-title":"J. Intern. Med."},{"key":"1197_CR124","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/gutjnl-2023-329998","volume":"72","author":"T Marjot","year":"2023","unstructured":"Marjot, T., Tomlinson, J. W., Hodson, L. & Ray, D. W. Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD. Gut 72, 1607\u20131619 (2023).","journal-title":"Gut"},{"key":"1197_CR125","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/nu11071500","volume":"11","author":"SD Anton","year":"2019","unstructured":"Anton, S. D. et al. The effects of time restricted feeding on overweight, older adults: a pilot study. Nutrients 11, 1500 (2019).","journal-title":"Nutrients"},{"key":"1197_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16220","volume":"45","author":"I Alabdul Razzak","year":"2025","unstructured":"Alabdul Razzak, I., Fares, A., Stine, J. G. & Trivedi, H. D. The role of exercise in steatotic liver diseases: an updated perspective. Liver Int. 45, e16220 (2025).","journal-title":"Liver Int."},{"key":"1197_CR127","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2024.06.017","volume":"81","author":"JM Mucinski","year":"2024","unstructured":"Mucinski, J. M. et al. Histological improvements following energy restriction and exercise: the role of insulin resistance in resolution of MASH. J. Hepatol. 81, 781\u2013793 (2024).","journal-title":"J. Hepatol."},{"key":"1197_CR128","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/jcsm.13225","volume":"14","author":"Y Shen","year":"2023","unstructured":"Shen, Y. et al. Exercise for sarcopenia in older people: a systematic review and network meta-analysis. J. Cachexia Sarcopenia Muscle 14, 1199\u20131211 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR129","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun, H. S. et al. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 21, 358\u2013369.e12 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1197_CR130","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","volume":"54","author":"FC Bull","year":"2020","unstructured":"Bull, F. C. et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 54, 1451\u20131462 (2020).","journal-title":"Br. J. Sports Med."},{"key":"1197_CR131","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCRESAHA.123.322121","volume":"132","author":"AS Perry","year":"2023","unstructured":"Perry, A. S. et al. Physical activity over the lifecourse and cardiovascular disease. Circ. Res. 132, 1725\u20131740 (2023).","journal-title":"Circ. Res."},{"key":"1197_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-020-01041-3","volume":"17","author":"C Sherrington","year":"2020","unstructured":"Sherrington, C. et al. Evidence on physical activity and falls prevention for people aged 65+ years: systematic review to inform the WHO guidelines on physical activity and sedentary behaviour. Int. J. Behav. Nutr. Phys. Act. 17, 144 (2020).","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"1197_CR133","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/jcsm.13359","volume":"14","author":"X Lai","year":"2023","unstructured":"Lai, X. et al. Dose-response effects of resistance training on physical function in frail older chinese adults: a randomized controlled trial. J. Cachexia Sarcopenia Muscle 14, 2824\u20132834 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2022.111767","volume":"163","author":"E Mende","year":"2022","unstructured":"Mende, E. et al. Progressive machine-based resistance training for prevention and treatment of sarcopenia in the oldest old: a systematic review and meta-analysis. Exp. Gerontol. 163, 111767 (2022).","journal-title":"Exp. Gerontol."},{"key":"1197_CR135","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MEG.0000000000002887","volume":"37","author":"DG Medeiros","year":"2025","unstructured":"Medeiros, D. G., Ferreira, L. F., Lamp, J. D. S. & Telles da Rosa, L. H. The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review. Eur. J. Gastroenterol. Hepatol. 37, 129\u2013136 (2025).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1197_CR136","doi-asserted-by":"publisher","first-page":"155597","DOI":"10.1016\/j.metabol.2023.155597","volume":"149","author":"Y Rolland","year":"2023","unstructured":"Rolland, Y., Dray, C., Vellas, B. & Barreto, P. S. Current and investigational medications for the treatment of sarcopenia. Metabolism 149, 155597 (2023).","journal-title":"Metabolism"},{"key":"1197_CR137","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Resmetirom: first approval. Drugs 84, 729\u2013735 (2024).","journal-title":"Drugs"},{"key":"1197_CR138","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1197_CR139","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29, 2919\u20132928 (2023).","journal-title":"Nat. Med."},{"key":"1197_CR140","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","volume":"82","author":"YH Zhang","year":"2024","unstructured":"Zhang, Y. H. et al. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J. Hepatol. 82, 189\u2013202 (2024).","journal-title":"J. Hepatol."},{"key":"1197_CR141","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1197_CR142","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70256","volume":"45","author":"A Mantovani","year":"2025","unstructured":"Mantovani, A. et al. Glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis: a meta-analysis of randomised controlled trials. Liver Int. 45, e70256 (2025).","journal-title":"Liver Int."},{"key":"1197_CR143","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1197_CR144","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1197_CR145","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","volume":"25","author":"A Bikou","year":"2024","unstructured":"Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K. & Kontogiorgis, C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin. Pharmacother. 25, 611\u2013619 (2024).","journal-title":"Expert Opin. Pharmacother."},{"key":"1197_CR146","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield, S. B. et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw. Open 4, e2033457 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1197_CR147","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05616013 (2024)."},{"key":"1197_CR148","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro, O. et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401, 1786\u20131797 (2023).","journal-title":"Lancet"},{"key":"1197_CR149","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly, G. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159, 1290\u20131301.e5 (2020).","journal-title":"Gastroenterology"},{"key":"1197_CR150","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06374875 (2024)."},{"key":"1197_CR151","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.clnesp.2022.03.009","volume":"49","author":"J Molero","year":"2022","unstructured":"Molero, J. et al. Prevalence of low skeletal muscle mass following bariatric surgery. Clin. Nutr. ESPEN 49, 436\u2013441 (2022).","journal-title":"Clin. Nutr. ESPEN"},{"key":"1197_CR152","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/jpm13050830","volume":"13","author":"L Valenzuela-Vallejo","year":"2023","unstructured":"Valenzuela-Vallejo, L., Sanoudou, D. & Mantzoros, C. S. Precision medicine in fatty liver disease\/non-alcoholic fatty liver disease. J. Pers. Med. 13, 830 (2023).","journal-title":"J. Pers. Med."},{"key":"1197_CR153","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000575","volume":"14","author":"R Zhou","year":"2023","unstructured":"Zhou, R. et al. Digital therapeutics: emerging new therapy for nonalcoholic fatty liver disease. Clin. Transl. Gastroenterol. 14, e00575 (2023).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"1197_CR154","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/nu9080913","volume":"9","author":"J de Toro-Martin","year":"2017","unstructured":"de Toro-Martin, J., Arsenault, B. J., Despres, J. P. & Vohl, M. C. Precision nutrition: a review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients 9, 913 (2017).","journal-title":"Nutrients"},{"key":"1197_CR155","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4093\/dmj.2023.0112","volume":"47","author":"J Mesinovic","year":"2023","unstructured":"Mesinovic, J. et al. Type 2 diabetes mellitus and sarcopenia as comorbid chronic diseases in older adults: established and emerging treatments and therapies. Diabetes Metab. J. 47, 719\u2013742 (2023).","journal-title":"Diabetes Metab. J."},{"key":"1197_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101585","volume":"30","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: results from NHANES 2017-2018. Ann. Hepatol. 30, 101585 (2024).","journal-title":"Ann. Hepatol."},{"key":"1197_CR157","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1021\/acssensors.4c03379","volume":"10","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. Porous-structure flexible muscle sensor for monitoring muscle function and mass. ACS Sens. 10, 5484\u20135494 (2025).","journal-title":"ACS Sens."},{"key":"1197_CR158","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s40520-025-03024-5","volume":"37","author":"J Guo","year":"2025","unstructured":"Guo, J., He, Q. & Li, Y. Machine learning-based online web calculator predicts the risk of sarcopenic obesity in older adults. Aging Clin. Exp. Res. 37, 210 (2025).","journal-title":"Aging Clin. Exp. Res."},{"key":"1197_CR159","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","volume":"29","author":"TJ Kendall","year":"2023","unstructured":"Kendall, T. J. et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat. Med. 29, 2939\u20132953 (2023).","journal-title":"Nat. Med."},{"key":"1197_CR160","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3390\/nu16162768","volume":"16","author":"V Yik","year":"2024","unstructured":"Yik, V. et al. Diagnosing sarcopenia with AI-aided ultrasound (DINOSAUR) \u2014 a pilot study. Nutrients 16, 2768 (2024).","journal-title":"Nutrients"},{"key":"1197_CR161","doi-asserted-by":"publisher","first-page":"108950","DOI":"10.1016\/j.cmpb.2025.108950","volume":"270","author":"D Kumar","year":"2025","unstructured":"Kumar, D., Bakariya, B., Verma, C. & Illes, Z. LivXAI-net: an explainable AI framework for liver disease diagnosis with IoT-based real-time monitoring support. Comput. Methods Prog. Biomed. 270, 108950 (2025).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"1197_CR162","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/bios15070410","volume":"15","author":"G Huang","year":"2025","unstructured":"Huang, G., Chen, X. & Liao, C. AI-driven wearable bioelectronics in digital healthcare. Biosensors 15, 410 (2025).","journal-title":"Biosensors"},{"key":"1197_CR163","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/s41591-025-03724-5","volume":"31","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. An adaptive AI-based virtual reality sports system for adolescents with excess body weight: a randomized controlled trial. Nat. Med. 31, 2255\u20132268 (2025).","journal-title":"Nat. Med."},{"key":"1197_CR164","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/eurheartj\/ehaa209","volume":"41","author":"J Li","year":"2020","unstructured":"Li, J. et al. The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. Eur. Heart J. 41, 2645\u20132656 (2020).","journal-title":"Eur. Heart J."},{"key":"1197_CR165","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s13534-025-00461-z","volume":"15","author":"J Shin","year":"2025","unstructured":"Shin, J. et al. A wearable approach for Sarcopenia diagnosis using stimulated muscle contraction signal. Biomed. Eng. Lett. 15, 443\u2013454 (2025).","journal-title":"Biomed. Eng. Lett."},{"key":"1197_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.70023","volume":"16","author":"K Charriere","year":"2025","unstructured":"Charriere, K. et al. ODIASP: an open-source software for automated SMI determination-application to an inpatient population. J. Cachexia Sarcopenia Muscle 16, e70023 (2025).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR167","first-page":"101025","volume":"20","author":"F Li","year":"2025","unstructured":"Li, F., Yuan, R., Zhang, J., Su, B. & Qi, X. Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease. Asian J. Pharm. Sci. 20, 101025 (2025).","journal-title":"Asian J. Pharm. Sci."},{"key":"1197_CR168","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3350\/cmh.2024.0854","volume":"31","author":"L Li","year":"2025","unstructured":"Li, L. et al. Stem cell exosomes: new hope and future potential for relieving liver fibrosis. Clin. Mol. Hepatol. 31, 333\u2013349 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1197_CR169","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1021\/acsbiomaterials.8b00652","volume":"4","author":"Q Wu","year":"2018","unstructured":"Wu, Q. et al. Establishment of an ex vivo model of nonalcoholic fatty liver disease using a tissue-engineered liver. ACS Biomater. Sci. Eng. 4, 3016\u20133026 (2018).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"1197_CR170","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s11739-023-03339-z","volume":"18","author":"G Tarantino","year":"2023","unstructured":"Tarantino, G., Sinatti, G., Citro, V., Santini, S. J. & Balsano, C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Intern. Emerg. Med. 18, 1887\u20131895 (2023).","journal-title":"Intern. Emerg. Med."},{"key":"1197_CR171","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1002\/jcsm.13076","volume":"13","author":"T Okamura","year":"2022","unstructured":"Okamura, T. et al. Brazilian green propolis improves gut microbiota dysbiosis and protects against sarcopenic obesity. J. Cachexia Sarcopenia Muscle 13, 3028\u20133047 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR172","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jcsm.13125","volume":"14","author":"HJ Choe","year":"2023","unstructured":"Choe, H. J., Lee, H., Lee, D., Kwak, S. H. & Koo, B. K. Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort. J. Cachexia Sarcopenia Muscle 14, 260\u2013269 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1197_CR173","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1017\/S0007114520004559","volume":"126","author":"F Gao","year":"2021","unstructured":"Gao, F. et al. FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. Br. J. Nutr. 126, 813\u2013824 (2021).","journal-title":"Br. J. Nutr."},{"key":"1197_CR174","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s12072-022-10384-x","volume":"16","author":"XY Pan","year":"2022","unstructured":"Pan, X. Y. et al. Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. Hepatol. Int. 16, 1085\u20131093 (2022).","journal-title":"Hepatol. Int."},{"key":"1197_CR175","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/ggi.14259","volume":"21","author":"T Minohara","year":"2021","unstructured":"Minohara, T. et al. Associations between genetic loci related to lean mass and body composition in type 2 diabetes. Geriatr. Gerontol. Int. 21, 932\u2013938 (2021).","journal-title":"Geriatr. Gerontol. Int."},{"key":"1197_CR176","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/gut.2009.190801","volume":"59","author":"P Dongiovanni","year":"2010","unstructured":"Dongiovanni, P. et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59, 267\u2013273 (2010).","journal-title":"Gut"},{"key":"1197_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1747","volume":"9","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. The association between sarcopenia susceptibility and polymorphisms of FTO, ACVR2B, and IRS1 in Tibetans. Mol. Genet. Genom. Med. 9, e1747 (2021).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1197_CR178","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/CIA.S254740","volume":"15","author":"Z Gu","year":"2020","unstructured":"Gu, Z. et al. FTO Polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) susceptibility in the older Chinese Han population. Clin. Interv. Aging 15, 1333\u20131341 (2020).","journal-title":"Clin. Interv. Aging"},{"key":"1197_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100437","volume":"2","author":"N Ghodsian","year":"2021","unstructured":"Ghodsian, N. et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep. Med. 2, 100437 (2021).","journal-title":"Cell Rep. Med."},{"key":"1197_CR180","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.3390\/jcm10214933","volume":"10","author":"P Khanal","year":"2021","unstructured":"Khanal, P. et al. Sarcopenia, obesity, and sarcopenic obesity: relationship with skeletal muscle phenotypes and single nucleotide polymorphisms. J. Clin. Med. 10, 4933 (2021).","journal-title":"J. Clin. Med."},{"key":"1197_CR181","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/liv.14543","volume":"40","author":"A De Vincentis","year":"2020","unstructured":"De Vincentis, A. et al. Genetic variants in the MTHFR are not associated with fatty liver disease. Liver Int. 40, 1934\u20131940 (2020).","journal-title":"Liver Int."},{"key":"1197_CR182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154337","volume":"11","author":"MY Sun","year":"2016","unstructured":"Sun, M. Y., Zhang, L., Shi, S. L. & Lin, J. N. Associations between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and non-alcoholic fatty liver disease (NAFLD) risk: a meta-analysis. PLoS ONE\u00a011, e0154337 (2016).","journal-title":"PLoS ONE"},{"key":"1197_CR183","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00421-010-1500-0","volume":"110","author":"MC Kostek","year":"2010","unstructured":"Kostek, M. C. et al. A polymorphism near IGF1 is associated with body composition and muscle function in women from the health, aging, and body composition study. Eur. J. Appl. Physiol. 110, 315\u2013324 (2010).","journal-title":"Eur. J. Appl. Physiol."},{"key":"1197_CR184","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/labmed\/lmac039","volume":"53","author":"H Nobakht","year":"2022","unstructured":"Nobakht, H. et al. Association of rs5742612 polymorphism in the promoter region of IGF1 gene with nonalcoholic fatty liver disease: a case-control study. Lab. Med. 53, 504\u2013508 (2022).","journal-title":"Lab. Med."},{"key":"1197_CR185","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/13813455.2020.1791187","volume":"129","author":"M Sabzikarian","year":"2023","unstructured":"Sabzikarian, M. et al. The common variant of rs6214 in insulin like growth factor 1 (IGF1) gene: a potential protective factor for non-alcoholic fatty liver disease. Arch. Physiol. Biochem. 129, 10\u201315 (2023).","journal-title":"Arch. Physiol. Biochem."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01197-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01197-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T01:03:00Z","timestamp":1771203780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01197-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":185,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1038\/s41574-025-01197-7","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"6 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.-H.Z. has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, and consulting fees from Boehringer Ingelheim and serves as a consultant for Eieling Technology. C.S.M. reports grants through his institution from Merck, Massachusetts Life Sciences Center and Boehringer Ingelheim, has received grants through his institution and personal consulting fees from Coherus Inc. and AltrixBio, reports personal consulting fees and support with research reagents from Ansh Inc., collaborative research support from LabCorp Inc., personal consulting fees from Olympus, Genfit, Lumos, Novo Nordisk, Amgen, Biodexa, Laekna, Corcept, Intercept, 89 Bio, Madrigal, Aligos, Esperion and Regeneron, travel support and fees from UptoDate, TMIOA, Elsevier and the Cardio Metabolic Health Conference. C.D.B. has received grant support from Echosens. W.K. reports grants from Glaxosmithkline, Gilead, Novartis, Pfizer, Roche, Springbank, Ildong, Galmed, Dicerna, Enyo, Hanmi, Novo Nordisk and KOBIOLABS; consulting fees from Boehringer Ingelheim, Novo Nordisk, Standigm, Daewoong, TSD Life Sciences Ildong, Olix Pharma, HK Inoen and KOBIOLABS; honoraria for lectures from Ildong, Samil and Novo Nordisk, owns stocks in KOBIOLABS and Lepidyne, and is the founder of Remedygen. S.U.K. reported honoraria from Gilead Sciences, GSK, Bayer, Eisai, AbbVie, EchoSens, MSD, BMS and AstraZeneca and grants from AbbVie, BMS and Gilead. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}